CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the "Company”), (formerly Blue ...
Onconetix (ONCO) announced that new clinical data of Proclarix was presented on March 23, 2025 during the 2025 European ...
Onconetix, Inc. CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics ...
Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has announced the presentation of new clinical data for Proclarix® during the 2025 European Association of Urology congress, showcasing its ...
Onconetix, Inc., (Nasdaq: ONCO) ("Onconetix" or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development ...
Onconetix, Inc., formerly Blue Water Biotech, announced that an abstract has been accepted for presentation at the 2025 European Association of Urology congress in Madrid. The presentation will ...
Onconetix (ONCO) announced that an abstract has been accepted for presentation at the 2025 European Association of Urology, EAU, congress ...
CINCINNATI - Onconetix, Inc. (NASDAQ:ONCO), a cancer diagnostics company currently trading at $0.13 per share with a market cap of just over $1 million, presented new clinical data for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback